ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2646

Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data

Luigi Boiardi1, Mariagrazia Catanoso 2, Giovanna Restuccia 3, Francesco Muratore 3, Pierluigi Macchioni 4 and Carlo Salvarani 5, 1Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, ITALY, Reggio Emilia, Italy, 3Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, 5Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: large vessel vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To investigate the relationship between demographical, clinical, laboratory and imaging data and survival in patients with large vessel giant cell arteritis (LVGCA) in a defined area of Northern Italy.

Methods: All patients with incident LVGCA diagnosed between 1 January 2005 and 31 December 2016 and living in the Reggio Emilia area, were identified by capture and re-capture checking of computerized discharge diagnosis codes (ICD10) and using outpatients databases from rheumatology, internal medicine, surgery, pathology, imaging departments of Reggio Emilia Hospital as well as by examining the Reggio Emilia district database for rare diseases. To be included in the study, patients must satisfy the following 2 criteria: age at disease onset ≥50 years; evidence of large-vessel vasculitis (LVV) by clinical criteria, angiography, MRA, CTA, PET/CT and/or ultrasonography. Demographic, clinical, laboratory and imaging data collected at first visit and during follow-up (FU) were retrived from patients records. For each case, we identified one control from the same geographic area matched for age and gender.  Mortality rates and specific causes of death were reported and compared between cases and controls. Demographical, clinical laboratory and imaging data entered in a Cox proportional regression analysis (CPRA) along with total corticosteroid (CS) cumulative dose, first 6 and 12 months cumulative CS dose, number of flares, and disease remission during the FU period.

Results: There were 93 incident cases of LVGCA (71% women, mean ± SD age at diagnosis 72 ± 9 years, mean duration of FU 65 + 38 months) with complete clinical, laboratory and survival data during the 12-year study period. During the FU period, 16 (17%) patients died (mean survival time from disease onset 16 + 12 months). At univariate analysis (UVA) factors significantly linked to survival (p< 0.05) were the presence of hypertrigliceridemia (HTG) and the involvement of brachio-cephalic artery (BCA). All the variables with a value of p< 0.20 at UVA (HTG, BCA, hypertension, concomitant PMR, cumulative CS dose at 6 and 12 months and aortic involvement) entered in a CPRA but none of them maintained statistical significance. Survival of LVGCA patients was not different from controls (logrank=0.004, p=0.947). The most frequent causes of death were cardiovascular diseases, cancer, and respiratory diseases. No significant differences in causes of death were observed comparing the patients with control population.

Conclusion: In an incident cohort of LVGCA we have not found any correlation between baseline and follow up clinical, demographical, laboratory and imaging data with survival.

Patients with LVCGA have no difference of survival time and causes of death with the control population.


Disclosure: L. Boiardi, None; M. Catanoso, None; G. Restuccia, None; F. Muratore, None; P. Macchioni, None; C. Salvarani, None.

To cite this abstract in AMA style:

Boiardi L, Catanoso M, Restuccia G, Muratore F, Macchioni P, Salvarani C. Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/survival-of-large-vessel-giant-cell-arteritis-in-northern-italy-during-a-26-year-period-no-correlation-with-demographical-clinical-laboratory-and-imaging-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-of-large-vessel-giant-cell-arteritis-in-northern-italy-during-a-26-year-period-no-correlation-with-demographical-clinical-laboratory-and-imaging-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology